TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: The ECHELON-2 trial has demonstrated that the addition of brentuximab vedotin, a CD30-directed antibody-drug conjugate, to the first-line therapy significantly improves survival in patients with CD30-positive PTCL (4).